Literature DB >> 16543541

Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.

D Fialho1, Y-C Chan, D C Allen, M M Reilly, R A C Hughes.   

Abstract

We discovered many reports of other immunosuppressive drugs being used in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but none of methotrexate. As weekly low dose oral methotrexate is safe, effective, and well tolerated in other diseases, we treated 10 patients with otherwise treatment resistant CIDP. Seven showed improvement in strength by at least two points on the MRC sum score and three worsened. Only two showed an improvement in disability and both were also receiving corticosteroids. We discuss the difficulty of detecting an improvement in treatment resistant CIDP and propose methotrexate as a suitable agent for testing in a randomised trial.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16543541      PMCID： PMC2077507          DOI： 10.1136/jnnp.2005.074781

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  I N Van Schaik; J B Winer; R De Haan; M Vermeulen
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 2.  Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R A C Hughes; A V Swan; P A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

3.  Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  C Meléndez-Vásquez; J Redford; P P Choudhary; I A Gray; P Maitland; N A Gregson; K J Smith; R A Hughes
Journal:  J Neuroimmunol       Date:  1997-03       Impact factor: 3.478

4.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R Hughes; S Bensa; H Willison; P Van den Bergh; G Comi; I Illa; E Nobile-Orazio; P van Doorn; M Dalakas; M Bojar; A Swan
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

Review 5.  Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.

Authors:  Frank L Mastaglia; Michael J Garlepp; Beverley A Phillips; Paul J Zilko
Journal:  Muscle Nerve       Date:  2003-04       Impact factor: 3.217

Review 6.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  M M Mehndiratta; R A Hughes
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  Experience with the use of low-dose methotrexate for inflammatory bowel disease.

Authors:  Su Yang Soon; Azhar Ansari; May Yaneza; Shariqa Raoof; Jo Hirst; Jeremy D Sanderson
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-09       Impact factor: 2.566

Review 8.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  M M Mehndiratta; R A C Hughes; P Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.

Authors:  P J Dyck; P O'Brien; C Swanson; P Low; J Daube
Journal:  Neurology       Date:  1985-08       Impact factor: 9.910

Review 10.  Methotrexate for multiple sclerosis.

Authors:  O Gray; G V McDonnell; R B Forbes
Journal:  Cochrane Database Syst Rev       Date:  2004
View more
  9 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Inna Kleyman; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 3.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 4.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 5.  Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  Richard Hughes
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 6.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

7.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 8.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

Review 9.  Progress in Hematopoietic Stem Cell Transplantation for CIDP.

Authors:  Zhen Qin; Qianyi Huang; Jiangying Zou; Lisha Tang; Zhiping Hu; Xiangqi Tang
Journal:  Int J Med Sci       Date:  2020-01-14       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.